DBV Technologies Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

DBV Technologies wird ein Gewinn- und Umsatzwachstum von 6.5% bzw. 59.6% pro Jahr prognostiziert, während der Gewinn pro Aktie sinken soll.

Wichtige Informationen

6.5%

Wachstumsrate der Gewinne

-11.3%

EPS-Wachstumsrate

Biotechs Gewinnwachstum	4.6%
Wachstumsrate der Einnahmen	59.6%
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Low
Zuletzt aktualisiert	25 Oct 2024

Jüngste Aktualisierungen zum künftigen Wachstum

DBV Technologies S.A. (EPA:DBV) Released Earnings Last Week And Analysts Lifted Their Price Target To €6.50

May 09

Recent updates

DBV Technologies S.A.'s (EPA:DBV) 41% Share Price Surge Not Quite Adding Up

Oct 24

Analysts Just Made A Major Revision To Their DBV Technologies S.A. (EPA:DBV) Revenue Forecasts

Aug 04

Risks To Shareholder Returns Are Elevated At These Prices For DBV Technologies S.A. (EPA:DBV)

Jun 14

We Think Shareholders Are Less Likely To Approve A Large Pay Rise For DBV Technologies S.A.'s (EPA:DBV) CEO For Now

May 10

DBV Technologies S.A. (EPA:DBV) Released Earnings Last Week And Analysts Lifted Their Price Target To €6.50

May 09

Some DBV Technologies S.A. (EPA:DBV) Analysts Just Made A Major Cut To Next Year's Estimates

Mar 14

DBV Technologies S.A. (EPA:DBV) Just Reported Earnings, And Analysts Cut Their Target Price

Mar 10

Here's Why We're Not Too Worried About DBV Technologies' (EPA:DBV) Cash Burn Situation

Oct 04

DBV Technologies S.A. (EPA:DBV) Shares Could Be 45% Below Their Intrinsic Value Estimate

Aug 06

Here's Why DBV Technologies (EPA:DBV) Must Use Its Cash Wisely

Mar 14

Gewinn- und Umsatzwachstumsprognosen

ENXTPA:DBV - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	6	-124	-183	-119	1
12/31/2025	5	-119	-172	-114	1
12/31/2024	5	-128	-160	-110	2
9/30/2024	13	-102	-109	-106	N/A
6/30/2024	14	-88	-105	-103	N/A
3/31/2024	15	-80	-95	-94	N/A
12/31/2023	16	-73	-80	-80	N/A
9/30/2023	6	-101	-90	-90	N/A
6/30/2023	5	-101	-91	-90	N/A
3/31/2023	4	-100	-76	-75	N/A
12/31/2022	5	-96	-56	-56	N/A
9/30/2022	9	-71	-52	-51	N/A
6/30/2022	8	-77	-55	-53	N/A
3/31/2022	5	-85	-74	-74	N/A
12/31/2021	6	-98	-109	-108	N/A
9/30/2021	2	-124	-124	-123	N/A
6/30/2021	4	-131	-144	-142	N/A
3/31/2021	9	-148	-154	-152	N/A
12/31/2020	11	-160	-168	-166	N/A
9/30/2020	17	-161	-157	-153	N/A
6/30/2020	16	-171	-156	-151	N/A
3/31/2020	16	-169	-161	-156	N/A
12/31/2019	15	-172	-154	-148	N/A
9/30/2019	12	-176	-156	-151	N/A
6/30/2019	13	-198	-176	-169	N/A
3/31/2019	13	-191	-166	-160	N/A
12/31/2018	13	-190	-162	-157	N/A
9/30/2018	11	-178	-164	-157	N/A
6/30/2018	11	-172	N/A	-145	N/A
3/31/2018	11	-182	N/A	-147	N/A
12/31/2017	12	-177	N/A	-137	N/A
9/30/2017	11	-169	N/A	-118	N/A
6/30/2017	11	-157	N/A	-97	N/A
3/31/2017	9	-135	N/A	-77	N/A
12/31/2016	8	-121	N/A	-63	N/A
9/30/2016	8	-109	N/A	-58	N/A
6/30/2016	8	-88	N/A	-49	N/A
3/31/2016	8	-72	N/A	-41	N/A
12/31/2015	7	-49	N/A	-29	N/A
9/30/2015	6	-40	N/A	-28	N/A
6/30/2015	6	-30	N/A	-25	N/A
3/31/2015	5	-27	N/A	-23	N/A
12/31/2014	6	-29	N/A	-25	N/A
9/30/2014	6	-30	N/A	-24	N/A
6/30/2014	7	-32	N/A	-25	N/A
3/31/2014	6	-28	N/A	-21	N/A
12/31/2013	5	-27	N/A	-18	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: DBV wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: DBV wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: DBV wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: DBVDie Einnahmen des Unternehmens (59.6% pro Jahr) werden voraussichtlich schneller wachsen als der Markt French (5.6% pro Jahr).

Hohe Wachstumseinnahmen: DBVDie Einnahmen des Unternehmens (59.6% pro Jahr) werden voraussichtlich schneller wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von DBV in 3 Jahren voraussichtlich hoch sein wird

DBV Technologies Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Price target decreased by 48% to €2.45

Consensus revenue estimates decrease by 18%

Consensus EPS estimates upgraded to US$0.74 loss, revenue downgraded

DBV Technologies S.A. (EPA:DBV) Released Earnings Last Week And Analysts Lifted Their Price Target To €6.50

Price target increased by 36% to €6.50

No longer forecast to breakeven

Recent updates

DBV Technologies Announces Plan to Implement ADS Ratio Change to Regain Compliance

Third quarter 2024 earnings released: US$0.32 loss per share (vs US$0.17 loss in 3Q 2023)

DBV Technologies S.A.'s (EPA:DBV) 41% Share Price Surge Not Quite Adding Up

New major risk - Revenue and earnings growth

Dbv Technologies Announces Positive Regulatory Updates for the Viaskin Peanut Patch in the United States and Europe

Price target decreased by 48% to €2.45

Consensus revenue estimates decrease by 18%

Analysts Just Made A Major Revision To Their DBV Technologies S.A. (EPA:DBV) Revenue Forecasts

Second quarter 2024 earnings released: US$0.34 loss per share (vs US$0.26 loss in 2Q 2023)

DBV Technologies S.A. to Report Q2, 2024 Results on Jul 30, 2024

New minor risk - Share price stability

DBV Technologies Provides Non-Compliance Update Related to Nasdaq Listing Rule 5550(a)(2) & 5810(c)(3)(A)

Risks To Shareholder Returns Are Elevated At These Prices For DBV Technologies S.A. (EPA:DBV)

Consensus EPS estimates upgraded to US$0.74 loss, revenue downgraded

We Think Shareholders Are Less Likely To Approve A Large Pay Rise For DBV Technologies S.A.'s (EPA:DBV) CEO For Now

DBV Technologies S.A. (EPA:DBV) Released Earnings Last Week And Analysts Lifted Their Price Target To €6.50

Price target increased by 36% to €6.50

First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

New major risk - Revenue and earnings growth

No longer forecast to breakeven

Insufficient new directors

DBV Technologies S.A., Annual General Meeting, May 16, 2024

New minor risk - Profitability

No longer forecast to breakeven

Some DBV Technologies S.A. (EPA:DBV) Analysts Just Made A Major Cut To Next Year's Estimates

DBV Technologies S.A. (EPA:DBV) Just Reported Earnings, And Analysts Cut Their Target Price

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Price target decreased by 17% to €4.43

New major risk - Financial position

DBV Technologies S.A. to Report Fiscal Year 2023 Results on Mar 07, 2024

Forecast to breakeven in 2026

DBV Technologies Receives a Letter from the Listing Qualifications Staff of the Nasdaq Stock Market

Is DBV Technologies (EPA:DBV) In A Good Position To Invest In Growth?

DBV Technologies S.A. to Present New Data at ACAAI 2023

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Consensus revenue estimates increase by 29%

DBV Technologies S.A. to Report Q3, 2023 Results on Oct 31, 2023

DBV Technologies S.A. Announces Executive Changes

DBV Technologies S.A. Announces Executive Changes

Dbv Technologies S.A. Receives Feedback from FDA on Design Elements for Viaskin Peanut Safety Studies

Second quarter 2023 earnings released: US$0.26 loss per share (vs US$0.35 loss in 2Q 2022)

DBV Technologies S.A. to Report First Half, 2023 Results on Jul 31, 2023

New minor risk - Shareholder dilution

Is DBV Technologies (EPA:DBV) In A Good Position To Invest In Growth?

Consensus revenue estimates increase by 18%

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Consensus revenue estimates decrease by 26%

We're Hopeful That DBV Technologies (EPA:DBV) Will Use Its Cash Wisely

Full year 2022 earnings: EPS and revenues miss analyst expectations

Price target increased to €5.64

Forecast to breakeven in 2025

DBV Technologies Announces FDA Lifts Partial Clinical Hold on VITESSE Phase 3 Pivotal Trial

Price target decreased to €5.16

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

DBV Technologies S.A. Announces Executive Changes

Here's Why We're Not Too Worried About DBV Technologies' (EPA:DBV) Cash Burn Situation

Consensus forecasts updated

DBV Technologies S.A. Receives Feedback from the U.S. Food and Drug Administration in the Form of a Partial Clinical Hold on Its VITESSE Phase 3 Clinical Study

DBV Technologies S.A. Announces Initiation of Phase 3 Study (VITESSE) Using the Modified Viaskin Peanut Patch in Peanut -Allergic Children Ages 4 to 7 Years

Consensus EPS estimates fall by 11%

Consensus revenue estimates increase by 53%

DBV Technologies S.A. (EPA:DBV) Shares Could Be 45% Below Their Intrinsic Value Estimate

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

DBV Technologies S.A. announced that it has received €82.00136 million in funding from Vivo Capital, LLC, RA Capital Management, L.P., VR Adviser, LLC, Baker Bros. Advisors LP, Braidwell LP, Fairmount Funds Management LLC

DBV Technologies S.A. announced that it expects to receive €82.00136 million in funding from Vivo Capital, LLC, RA Capital Management, L.P., VR Adviser, LLC, Baker Bros. Advisors LP, Braidwell LP, and other investor

DBV Technologies S.A. announced that it expects to receive €82.00136 million in funding from Vivo Capital, LLC, RA Capital Management, L.P., VR Adviser, LLC, Baker Bros. Advisors LP, Braidwell LP, and other investor

DBV Technologies Announces Positive Topline Results from Phase 3 Epitope Trial of Viaskin Peanut in Peanut-Allergic Toddlers

Consensus forecasts updated

First quarter 2022 earnings: EPS and revenues exceed analyst expectations